BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX) today announced FDA approval of a supplemental Biologics License Application (BLA) for a unit dose preservative free Tetanus Diphtheria vaccine. Akorn expects to launch this new vaccine in the first quarter of 2008.
